Mr Matthew Liew

Professional statement

Mr Matthew Liew is a highly accomplished and experienced consultant urologist  specialising in prostate cancer, bladder cancer, urinary tract infections, kidney stones, circumcision, as well as holmium laser prostate surgery (HoLEP). He is based in Warrington and Manchester, and practises at both the Spire Cheshire Hospital and the Spire Manchester Hospital. He also practises for the NHS at Liverpool University Hospital Foundation Trust.

Mr Liew completed both a MBBS and BMedSci(Hons-first class) degrees at Bart’s and the Royal London Hospital. He has expertise in benign prostate (BPH) surgery, en-bloc bladder tumour resection, transurethral laser ablation (TULA), as well as comprehensive kidney stone management. He is a fully accredited Royal College of Surgeons educational supervisor, as well as a key opinion leader in Endourology. In his NHS practice, he is urology lead for BPH Surgery, Endourology, Teaching, Research and Innovation.

Mr Liew is an incredibly active and renowned researcher, having published over 30 publications on a range of topics, including prostate cancer, kidney stone disease, and education. He is the current Principal Investigator in a number of key international Trials, and Chief Investigator of a bladder cancer trial investigating key risk factors in developing the disease. Impressively, he dedicated time to carry out formal research studying kidney cancer chemotherapy resistance mechanisms at the Christie Hospital, leading to a ‘doctor of medicine’ (MD) award from the University of Manchester in 2013.

He is an associate member of the European Association of Urology Guidelines Panel for Prostate Cancer, Review Editor for Frontiers in Urology Journal and frequently reviews articles for the British Journal of Urology International. He has carried out a number of UK first evaluations, including the use of a novel circumcision procedure. During 2021, Mr Liew was running the only non-cancer urology trial in the UK.